Therapy Detail

Therapy Name WZ4003
Therapy Description

WZ4003 inhibits NUAK1 and NUAK2, resulting in decreased cell proliferation and migration (PMID: 24171924).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
WZ4003 WZ4003 inhibits NUAK1 and NUAK2, resulting in decreased cell proliferation and migration (PMID: 24171924).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown osteosarcoma not applicable WZ4003 Preclinical - Cell culture Actionable In a preclinical study, WZ4003 inhibited MYPT1 phosphorylation and reduced invasive behavior and proliferation of an osteosarcoma cell line in culture (PMID: 24171924). 24171924
Clinical Trial Phase Therapies Title Recruitment Status